Fig. 3
10-year outcomes according to induction regimen. a Freedom from acute rejection. b Death-censored graft survival. c Patient survival. d All-cause graft survival. Basi, basiliximab; rATG, rabbit antithymocyte globulin
Fig. 3 | Trials